OPG/RANKL/RANK pathway as a therapeutic target in cancer

Emmet McGrath

Research output: Contribution to journalArticle

21 Citations (Scopus)


Bone metastases play an important role in the morbidity and mortality of patients with malignant disease. Despite therapeutic advances in the treatment of solid organ malignancy such as lung cancer, less development on metastasis interventions has been forthcoming. More recent research has focused on molecular pathway manipulation in the prevention and treatment of metastatic bone disease and associated complications such as bone pain and hypercalcemia. The osteoprotegerin/receptor activator of nuclear factor-кβ ligand/receptor activator of nuclear factor-кβ pathway, which is physiologically involved in bone turnover, has been of considerable interest, and recent promising data have been revealed. In this study, we describe this molecular pathway in terms of its natural physiological function, manipulation for therapeutic benefit, and recent clinical trial results.
Original languageEnglish
Pages (from-to)1468-73
Number of pages6
JournalJournal of Thoracic Oncology
Issue number9
Publication statusPublished - 1 Sept 2011


Dive into the research topics of 'OPG/RANKL/RANK pathway as a therapeutic target in cancer'. Together they form a unique fingerprint.

Cite this